{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=97", "query": { "condition": "Multiple Cancers", "page": 97 }, "page_size": 10 }, "pagination": { "page": 97, "page_size": 10, "total_count": 4780, "total_pages": 478, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=98&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Cancers&page=96&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T03:49:23.600Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00312377", "title": "ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1690, "start_date": "2006-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 27, "location_summary": "Fullerton, California • Los Angeles, California • Northridge, California + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00312377" }, { "nct_id": "NCT02886572", "title": "SIMT Stereotactic Radiosurgery Outcomes Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Metastases, Adult" ], "interventions": [ { "name": "Stereotactic radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-01-25", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2022-06-01", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02886572" }, { "nct_id": "NCT05705505", "title": "Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrioid Endometrial Cancer" ], "interventions": [ { "name": "Narazaciclib", "type": "DRUG" }, { "name": "Letrozole 2.5mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": "2023-03-29", "completion_date": "2026-02", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 8, "location_summary": "Tucson, Arizona • Minneapolis, Minnesota • Mineola, New York + 5 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705505" }, { "nct_id": "NCT03024866", "title": "Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nonmelanoma Skin Cancer" ], "interventions": [ { "name": "Electronic Brachytherapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Xoft, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "41 Years", "maximum_age": null, "sex": "ALL", "summary": "41 Years and older" }, "enrollment_count": 369, "start_date": "2016-10", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 4, "location_summary": "Los Gatos, California • San Diego, California • Las Vegas, Nevada", "locations": [ { "city": "Los Gatos", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03024866" }, { "nct_id": "NCT00003401", "title": "Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": null, "start_date": "1999-01", "completion_date": "2002-09", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003401" }, { "nct_id": "NCT06549751", "title": "MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer", "Pancreatic Cancer Metastatic", "Pancreatic Cancer (Unresectable)" ], "interventions": [ { "name": "MT-601 dose 200 million cells", "type": "DRUG" }, { "name": "MT-601 dose 400 million cells", "type": "DRUG" }, { "name": "MT-601 dose 800 million cells", "type": "DRUG" }, { "name": "MT-601 dose 1200 million cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marker Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2026-07-16", "completion_date": "2028-09-16", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06549751" }, { "nct_id": "NCT00777153", "title": "Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Lomustine Chemotherapy", "type": "DRUG" }, { "name": "Placebo Cediranib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 423, "start_date": "2008-10", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2016-12-28", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pheonix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00777153" }, { "nct_id": "NCT05064553", "title": "ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Hepatitis B", "Cirrhosis", "Liver Cancer" ], "interventions": [ { "name": "Study CT/MRI Imaging", "type": "DEVICE" }, { "name": "Standard of Care CT/MRI Imaging", "type": "DEVICE" }, { "name": "Oncoguard™ Liver Test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST" ], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2990, "start_date": "2021-07-26", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 76, "location_summary": "Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064553" }, { "nct_id": "NCT06892522", "title": "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "ABBV-2001", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2025-06-30", "completion_date": "2036-03", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 15, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06892522" }, { "nct_id": "NCT02417129", "title": "BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "BI 695500", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2, "start_date": "2015-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-11-11T03:49:23.600Z", "location_count": 13, "location_summary": "Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Albany", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02417129" } ] }